EDIT (Editas Medicine, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by EDIT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2026-09-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-09-04 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2026-08-07 | Patrick Thomas Ellinor II | Director | A | — | — |
| 2026-08-07 | Patrick Thomas Ellinor II | Director | A | — | — |
| 2026-08-05 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2026-07-29 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-06-22 | Jessica Hopfield | Director | A | — | — |
| 2026-06-22 | Elliott M. Levy | Director | A | — | — |
| 2026-06-22 | Andrew Hirsch | Director | A | — | — |
| 2026-06-22 | Bernadette Connaughton | Director | A | — | — |
| 2026-06-22 | David Scadden | Director | A | — | — |
| 2026-06-05 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2026-06-05 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2026-06-05 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-03-16 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2026-03-16 | Amy Parison | SVP, Chief Financial Officer | A | — | — |
| 2026-03-16 | Gilmore Neil O'Neill | CEO | A | — | — |
| 2026-03-04 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2026-03-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-03-04 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2025-12-04 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2025-12-04 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2025-12-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-09-04 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2025-09-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-09-04 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2025-08-08 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2025-08-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-06-10 | Jessica Hopfield | Director | A | — | — |
| 2025-06-10 | Bernadette Connaughton | Director | A | — | — |
| 2025-06-10 | Elliott M. Levy | Director | A | — | — |
| 2025-06-10 | Andrew Hirsch | Director | A | — | — |
| 2025-06-10 | David Scadden | Director | A | — | — |
| 2025-06-04 | Amy Parison | SVP, Chief Financial Officer | Sell | — | — |
| 2025-06-04 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2025-06-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-04-08 | Amy Parison | SVP, Chief Financial Officer | A | — | — |
| 2025-03-27 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-03-27 | Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-03-27 | Gilmore Neil O'Neill | CEO | A | — | — |
| 2025-03-05 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-03-05 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2025-03-05 | Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2024-12-05 | Baisong Mei | EVP, CHIEF MEDICAL OFFICER | Sell | — | — |
| 2024-12-05 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2024-09-06 | Baisong Mei | EVP, CHIEF MEDICAL OFFICER | Sell | — | — |
| 2024-09-06 | Gilmore Neil O'Neill | CEO | Sell | — | — |
| 2024-07-26 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2024-07-22 | Baisong Mei | EVP, CHIEF MEDICAL OFFICER | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,439,209 | — |
| — | 10%+ Owner | 4,002,144 | — |
| — | 10%+ Owner | 3,906,176 | — |
| — | 10%+ Owner | 3,906,176 | — |
| — | 10%+ Owner | 3,797,144 | — |
| — | — | 2,991,255 | — |
| — | — | 2,966,387 | — |
| — | 10%+ Owner | 2,953,687 | — |
| — | Director | 2,797,144 | — |
| — | 10%+ Owner | 2,786,967 | — |
| — | 10%+ Owner | 2,744,880 | — |
| — | Director | 2,684,572 | — |
| — | 10%+ Owner | 2,649,572 | — |
| — | President and CEO | 1,204,966 | — |
| — | 10%+ Owner | 854,700 | — |
| — | CEO | 243,189 | — |
| — | EVP, CHIEF MEDICAL OFFICER | 133,354 | — |
| — | Chief Operating Officer | 117,788 | — |
| — | EVP, CHIEF FINANCIAL OFFICER | 112,720 | — |
| — | EVP, CHIEF FINANCIAL OFFICER | 106,610 | — |
| — | CEO | 75,898 | — |
| — | EVP, CBO AND CTO | 74,791 | — |
| — | Director | 67,700 | — |
| — | EVP, CHIEF SCIENTIFIC OFFICER | 65,559 | — |
| — | EVP, CHIEF SCIENTIFIC OFFICER | 61,660 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EDIT quote page; the site-wide leaderboard is on the insider transactions hub.